+44 (0)1509 263171
Please use this identifier to cite or link to this item:
|Title: ||Serum-free process development: improving the yield and consistency of human mesenchymal stem cell production|
|Authors: ||Heathman, Thomas R.J.|
Rafiq, Qasim A.
Nienow, Alvin W.
Hewitt, Christopher J.
Human mesenchymal stem cell
|Issue Date: ||2015|
|Publisher: ||© Elsevier|
|Citation: ||HEATHMAN, T.R.J. ...et al., 2015. Serum-free process development: improving the yield and consistency of human mesenchymal stem cell production. Cytotherapy, 17(11), pp.1524-1535.|
|Abstract: ||Background: The cost effective production of hMSCs for off-the-shelf and patient specific therapies will require an increasing focus on improving product yield and driving manufacturing consistency.
Methods: Bone-marrow derived hMSCs from two donors were expanded for 36 days in monolayer with medium supplemented with either fetal bovine serum (FBS) or PRIME-XV® Serum-free Medium (SFM). Cells were assessed throughout culture for proliferation, mean cell diameter, colony forming potential, osteogenic potential, gene expression and metabolites.
Results: Expansion of BM-hMSCs in PRIME-XV® SFM resulted in a significantly higher growth rate (p < 0.001) and increased consistency between donors compared with FBS-based culture. FBS-based culture showed an inter batch production range of 0.9 and 5 days per dose compared with 0.5 and 0.6 days in SFM for each BM-hMSC donor line. The consistency between donors was also improved by the use of PRIME-XV® SFM, with a production range of 0.9 days compared with 19.4 days in FBS-based culture. Mean cell diameter has also been demonstrated as a process metric for BM-hMSC growth rate and senescence via a correlation (R2 = 0.8705) across all conditions. PRIME-XV® SFM has also shown increased consistency in BM-hMSC characteristics such as per cell metabolite utilisation, in vitro colony forming potential and osteogenic potential despite the higher number of population doublings.
Conclusions: We have increased the yield and consistency of BM-hMSC expansion between donors, demonstrating a level of control over the product, which has the potential to increase the cost effectiveness and reduce the risk in these manufacturing processes.|
|Description: ||This is an Open Access Article. It is published by Elsevier under the Creative Commons Attribution 4.0 Unported Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/|
|Sponsor: ||This study has been funded by the Engineering and Physical Sciences Research Council (EPSRC) and FUJIFILM Diosynth Biotechnologies.|
|Version: ||Published publication|
|Publisher Link: ||http://dx.doi.org/10.1016/j.jcyt.2015.08.002|
|Appears in Collections:||Published Articles (Mechanical, Electrical and Manufacturing Engineering)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.